Skeletal muscle loss appears to be the most significant event in cancer cachexia and is associated with a poor outcome. The balance between mechanisms that control synthesis and degradation is fundamental when designing new therapies. This review aims to highlight the molecular mechanisms that are associated with protein kinetics.
INTRODUCTION
Cachexia affects the majority of patients with advanced cancer and is a significant cause of morbidity and mortality [1, 2] . A recent international consensus study defined cancer cachexia as 'a multifactorial syndrome characterized by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. The pathophysiology is characterized by a negative protein and energy balance driven by a variable combination of reduced food intake and abnormal metabolism' [3 && ]. Patients may present with varying degrees of weight/tissue loss, and it is important to consider cachexia as a journey rather than an event.
Although there is depletion of both adipose tissue and lean body mass, it is skeletal muscle loss that has the greatest impact on patients and is associated with a poor outcome [3 && ,4,5 & ]. Skeletal muscle is the major reservoir of body proteins, consisting of around 640 separate muscles which account for 40% of total body weight or 50% of fat-free mass. In healthy adults, skeletal muscle mass is maintained by nutritional status and physical activity, reflecting a dynamic balance between protein synthesis and degradation. A predominance of either will result in muscle hypertrophy or atrophy. Even small changes in protein synthesis or degradation will lead to large protein deficits over time due to the continuous process of protein turnover. The myofibril is the base unit of muscle comprising thick (predominantly myosin) and thin (predominantly actin) filaments. Myofibrillar proteins account for more than 50% of protein in skeletal muscle and are integral to muscle contraction and function. The preservation or loss of these proteins will dictate the clinical symptoms and there is some evidence that they are selectively targeted in cancer cachexia [6, 7] .
This review aims to detail some of the recent advances in muscle protein biology and how emerging techniques and therapies seek to manipulate these complex biological pathways to attenuate skeletal muscle loss.
MUSCLE PROTEIN KINETICS IN THE HEALTHY ADULT
Insulin is the most important endocrine factor controlling skeletal muscle protein synthesis (MPS) in the active, well fed, healthy adult. Reduced peripheral insulin sensitivity is described in terms of reduced glucose clearance by peripheral tissues, predominantly skeletal muscle. Glucose uptake and amino acid uptake are both under insulin control and impaired MPS can accompany reduced insulin sensitivity. In patients with reduced peripheral insulin sensitivity, its normalisation may improve skeletal MPS.
QUANTIFICATION OF MUSCLE KINETICS
The understanding of the molecular biology of muscle wasting has increased significantly recently and this increase has identified a variety of potential drug targets in the complex pathways that control muscle hypertrophy/atrophy. It has been suggested that specific elements of the myofibrillar complex may be targeted early in the wasting process (e.g. myosin heavy chain). Clinical trial methodology is, however, limited by the absence of good biomarkers to predict early response and/or determine the net effect of combination therapy. Measurement of skeletal MPS (and perhaps specifically the myofibrillar protein myosin) may allow not only better understanding of the pathophysiology of muscle wasting in cachexia but also provide an early index of the response to muscle-directed therapy. Measurement of protein fractional synthetic rate (FSR) involves analysis of the increase in proteinbound amino acid (product) enrichment with time with respect to that of the tracer amino acid in the intracellular pool (precursor). Human skeletal muscle myosin FSR is low, of the order of 1% day [8] . Deuterium oxide (heavy water) can be used as an intrinsic tracer, labelling precursors of nonessential amino acids. Water mixes fully within an hour, it does not stimulate metabolic processes and eliminates slowly at a predictable rate. Single or multiple oral doses are given. Nonessential amino acids incorporate deuterium during de-novo synthesis. In the case of alanine, four hydrogen atoms come into equilibrium with body water and are incorporated into protein. This approach was first exploited to study protein synthesis in cell cultures and rodent models [9] . Low levels of tracer may best be measured after isolating and hydrolysing the protein and analysing individual amino acids, most probably alanine. Gas chromatography mass spectrometry (GCMS) can detect enrichments down to approximately 0.5 molar % excess in individual amino acids [9] . The newer GC-pyrolysis-isotope ratio mass spectrometry (IRMS) technique can detect ppm changes in deuterium in individual molecules. This technique is most suitable for measuring synthesis in major proteins available at high concentration [10] . Previs et al. [11] were the first to use 2H 2 O and GCMS to measure human albumin synthesis. GC-pyrolysis-IRMS was first shown capable of measuring de novo lipogenesis in a heavy water protocol in human patients [12] . Its use to measure tissue protein synthesis in humans is under development [13] . In contrast, modern proteomics platforms, either high resolution or tandem mass spectrometry can be used to measure stable isotope enrichment in several intact peptides simultaneously. As the labelled amino acids may be minor components of each peptide, minimum enrichments of approximately 5 molar % in that amino acid may be necessary for detection. However, modern instrumentation can detect very low peptide concentrations. Initial studies have been conducted in rodents [14, 15] . In summary, GC-pyrolysis-IRMS may be necessary to analyse low tracer enrichment human proteins present at high concentration, whereas proteomics platforms are compatible and may be used to measure to measure peptides at low concentration but with high synthetic rate. GCMS can be applied at intermediate enrichments. A
KEY POINTS
Skeletal muscle loss is one of the most significant events in cancer cachexia and is associated with a poor outcome.
The balance between mechanisms controlling synthesis and degradation is fundamental when designing new therapies.
Specific advances in cellular signalling molecules related to autophagy pathways including STAT3, ACTRIIB, TRAF6 and transcriptomic research are potential targets for development of therapeutics.
Development of novel tracer techniques will enable invivo quantification of muscle kinetics which will guide the efficacy and development of molecular therapeutics.
further consideration is that organic mass spectrometry (GCMS or liquid chromatography-mass spectrometry) allows isotopomer analysis to verify the labelling pattern of precursor and product [9] . A single oral 2H 2 O bolus can raise body water up to 2000 ppm excess 2 H (0.2 atom % 2 H excess). Greater enrichments may require multiple oral doses to avoid transient feelings of vertigo or nausea in a small proportion of patients. In adults, water half elimination time of some 7-8 days is typical. Measurement of MPS by 2H 2 O incorporation can either be made using a single bolus with a slow and predictable decline in precursor enrichment [13] or further boli can be taken on a daily basis [9] to produce a 'pseudoplateau' in body water enrichment. An advantage of the former approach is that total body water can be measured by deuterium dilution simultaneously with protein synthesis. In the context of a study to measure skeletal muscle protein fractional synthetic rate, this presents a means of estimating skeletal muscle mass from its proportion to fat-free mass, which has been validated using MRI data [16] , and thus estimating absolute MPS.
MUSCLE PROTEIN KINETICS IN CANCER CACHEXIA
In cachexia, there is an ongoing debate as to whether a reduction in protein synthesis, an increase in protein degradation or a combination of both is more relevant. Although evidence continues to emerge, it would appear that many of the relevant pathways are influenced by the presence of systemic inflammation [17] [18] [19] . Inflammatory-mediated signalling may limit MPS by several mechanisms. Tumour necrosis factor (TNF) a can activate the transcription factor nuclear factor kappa B (NF-kB), which inhibits the synthesis of the muscle-specific transcription factor MyoD, thereby inhibiting differentiation [20] , the transforming growth factor (TGF)-b family members induce muscle wasting downstream of SMAD activation [21 & ], and interleukin-6 activates signalling by binding to ligand-specific receptors either in soluble or membrane-bound forms to induce the signal transducers and activators of transcription-1 and transcription-3 (STAT1/3), extracellular-signal-regulated kinases (ERK) and phosphatidylinositol 3-kinase (PI3K) AKT pathways [22, 23] (Fig. 1) . The ERK pathway has been previously implicated in cancer cachexia and muscle wasting [24] , and the AKT pathway is primarily responsible for anabolism in skeletal muscle [25] .
PROTEOLYTIC PATHWAYS
Many research groups have focussed investigation on mechanisms responsible for skeletal muscle protein degradation in cancer cachexia. Although there are four mammalian proteolytic enzyme systems (the proteasome, lysosomal/autophagy pathway, caspases and calpains), it is the proteasome and lysosomal pathways which have received most attention.
The majority of signalling pathways contributing to muscle atrophy in preclinical models is mediated through activation of the ubiquitinproteasome proteolytic pathway (UPP) [26, 27] . The muscle-specific E3 ubiquitin ligases, MuRF-1 and MAFbx/atrogin-1 are upregulated in animal models of atrophy [28, 29] , and MuRF1 selectively targets the myofibrillar protein myosin heavy chain, resulting in muscle wasting [6, 7] . However, the role of the E3 ligases in human cachexia is less well defined. Studies that included patients following bed rest, limb amputation for vascular disease, limb immobilisation, chronic obstructive pulmonary disease, amyotrophic lateral sclerosis and ageing demonstrate both increased and decreased expression of MuRF1 and MAFBx [30] [31] [32] [33] but evidence for an increase in human cancer cachexia is lacking [34] . There are also data that suggest dissociation between protein dynamics in vivo and activation of UPP signalling in human skeletal muscle [35] .
Upstream of the E3 ligases, the insulin-regulated transcription factors FOXO1 and FOXO3a have been shown to increase expression of MuRF1 and MAFbx in animal models of cachexia [36, 37] . Furthermore, in both myotube and mouse models of muscle atrophy, several autophagy genes are upregulated appear to be under control of FOXO3 [36] [37] [38] [39] , linking the autophagy and proteasomal systems. This situation makes the FOXO transcription factors attractive therapeutic targets and indeed, early evidence of FOXO inhibition in preclinical models is promising [40 & ]. In cancer patients, there are few studies relating to the role of the autophagy pathway in muscle wasting. Increased cathepsin D and acid phosphatase activity has been demonstrated in patients with varying tumour types and degrees of weight loss [41] , and lung cancer patients undergoing resection were shown to have increased levels of cathepsin B [42] . Likewise, expression of the autophagy-related genes GABARAPL1 and BNIP3 has been associated with the presence of systemic inflammation and/or weight loss [34] , suggesting a potential role in the development of human cancer cachexia.
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wasting and the acute phase response in cancer cachexia [43 && ]. This contemporary study characterized serum cytokines and the muscle transcriptome in the colon-26 adenocarcinoma model of cancer cachexia. They provided evidence of STAT3 activation, target gene expression and the acute phase response in both liver and skeletal muscle in these mice, providing a molecular link between them. In addition to this finding, it was also shown that transcription of SOCS3, a classical feedback inhibitor of STAT3 activation, was significantly induced. SOCS3 binds to activated JAKs and inhibits STAT3 activation [44] . However, in contrast to the high SOCS3 mRNA levels in muscle, little to no increase in SOCS3 protein either in muscle or in liver was observed. This lack of SOCS3 protein explains in part how high pSTAT3 levels could persist regardless of high SOCS3 RNA levels and how sustained STAT3 activation might continue to drive muscle wasting while activating its inhibitor.
ACTIVIN TYPE-2 RECEPTOR
Myostatin and activin are two members of the TGF-b superfamily that play an important role in growth and are thought to be responsible for the development of cachexia in mice that lack the hormone inhibin [45] . Both molecules bind to activin type-2 receptor (ActRIIB), a receptor in muscle, to initiate a signalling cascade leading to increased expression of atrogin-1 and MuRF1 and subsequent degradation of myofibrillar proteins [25] . Direct evidence linking muscle wasting to survival of the patient with cancer cachexia has been lacking until recently [46,47 && ,48,49 & ]. One particular study in murine colon-26 carcinoma-bearing mice found that preservation of muscle mass is vitally important in the organism's survival. This experimental evidence suggests that ActRIIB antagonism prolonged survival, prevented muscle wasting and reversed muscle loss during cancer cachexia. Further work demonstrated that ActRIIB pathway activation induced the ubiquitin ligases critical in muscle wasting and enhanced ubiquitination of muscle proteins; these effects were completely abolished by ActRIIB antagonism. They also showed in the tumour-bearing mice, that ActRIIB-SMAD signalling stimulated FOXO3 activity in muscle, which induced transcription of atrogin-1 and MuRF1. Finally, they were able to show that ActRIIB antagonism dramatically stimulated satellite cell proliferation, which presumably contributes to rapid reversal of muscle loss in the treated animals. On the basis of these findings, development of treatments that block these catabolic actions of tumours should be explored as a potential therapeutic avenue.
MYOSTATIN
Myostatin and activin have also both been shown to be expressed 50-100-fold higher in both subcutaneous and visceral adipose tissue in obesity [7] . These results demonstrate that expression of myostatin and activin can be modulated in adipose tissue and skeletal muscle by chronic obesity and suggest that alterations in their expression may contribute to the changes in growth and metabolism of lean and fat tissues occurring during both obesity and cachexia [7] . On the basis of these observations, a therapeutic role for a myostatin antagonist exists and may prove of benefit in patients suffering from cancer cachexia.
TRAF6
TNF receptor-associated factors are proteins involved in activation of various intracellular signalling. TRAF6 is an important E3 ubiquitin ligase, which targets proteins for degradation [50, 51] . Several studies have shown TRAF6 to be related to activation of NF-kB, mitogen activated protein kinase and PI3K/AKT pathways [52, 53] . TRAF6 expression level and autoubiquitination have been shown to be enhanced in skeletal muscle during atrophy in mice [54] . This study also demonstrated that through the activation of JNK1/2, p38 mitogenactivated protein kinase, adenosine monophosphate-activated protein kinase, and NF-kB, skeletal muscle-restricted depletion of TRAF6 rescues myofibril degradation and preserves muscle fibre size and strength upon denervation [54] . Inhibition of TRAF6 also preserves the orderly pattern of intermyofibrillar and subsarcolemmal mitochondria in denervated muscle. This finding is direct evidence that depletion of TRAF6 prevents cancer cachexia in an experimental mouse model and provides a novel therapeutic target for prevention of skeletal muscle wasting in cancer cachexia.
CANDIDATE GENE IDENTIFICATION
Primary investigations to shed light on the detailed mechanisms that produce cancer cachexia in patients are increasing. With the development of high-throughput technologies such as genome sequencing, microarray gene expression studies and quantitative trait locus mapping, new hypotheses may be established and subsequently investigated in much more detail than previously possible. This development has been based largely on these high-throughput experiments, generating vast quantities of data [55] . In a recent transcriptomics study, the expression of 74 genes correlated positively with weight loss in cancer cachexia patients, and that of nine correlated negatively with it [34] . The most significantly positively correlated gene with weight loss, CAMK2B, encodes calcium/calmodulindependent protein kinase II b (CaMKIIb), a serine/ threonine protein kinase that is activated by Ca 2þ / calmodulin, leading to autophosphorylation and maintenance of CaMKII activity even after the Ca 2þ signal has diminished [56] . CaMKIIb is expressed in skeletal muscle. Levels of the protein as well as its phosphorylation status and activity increase after exercise training [57] . In addition, it has recently been demonstrated that Ca 2þ -CaM-eEF2K signalling may be responsible for acute exercise-induced inhibition of MPS, and it is, thus, conceivable that chronic inappropriate activation of this 'endurance training'-related signalling molecule subdues normal maintenance of skeletal muscle mass. Additional factors that could modulate CaMKII activity include alterations in lipid metabolism [58] .
Finally, CaMKII has also been implicated in muscle adaptation through phosphorylation of HDAC5 leading to MyoD/myocyte enhancer factor-2-driven differentiation of muscle cells [59] . CAMK2B may, thus, have an important role in regulating skeletal muscle function and metabolism. In a recent followup study, metabolic and protein turnover-related pathways were found to be suppressed in weightlosing patients with upper gastrointestinal cancer (UGIC), whereas removal of the cancer appeared to facilitate a return to a healthy state, independent of changes in the level of physical activity [60 && ].
CONCLUSION
Circulating mediators in differing concentrations, interplay of synthesis and degradation pathways, and novel gene identification are just some ways in which body composition, particularly involving muscle kinetics are regulated. Although cachectic cancer patients demonstrate systemic inflammation, increased lipolysis and insulin resistance [61] , there has been little effort until recently to exploit regulation of muscle mass for therapeutic gain. Treating clinicians have traditionally focused on curing cancer leaving the cachexia to take care of itself. However, symptom management on its own can improve survival in advanced cancer [62] , and multimodal management of cachexia has prompted an increasing number of phase I/II studies using highly specific/potent therapeutics targeted at either upstream mediators or downstream endorgan hypoanabolism/hypercatabolism. Currently, to treat muscle wasting, much of the outcome evidence is based upon observations on loss of muscle mass. However, with the development of novel tracer techniques, quantification of muscle kinetics can be established which will guide the efficacy and development of molecular therapeutics. The recent work into the regulation of muscle in this review, suggests that understanding of the integrative physiology of this complex system may yet lead to further developments of novel therapeutics, particularly for those patients suffering from clinically relevant muscle loss.
